WO2003002565A1 - 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders - Google Patents
2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders Download PDFInfo
- Publication number
- WO2003002565A1 WO2003002565A1 PCT/GB2002/002962 GB0202962W WO03002565A1 WO 2003002565 A1 WO2003002565 A1 WO 2003002565A1 GB 0202962 W GB0202962 W GB 0202962W WO 03002565 A1 WO03002565 A1 WO 03002565A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nhch
- mmol
- compound
- vacuo
- stirred
- Prior art date
Links
- 230000002062 proliferating effect Effects 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 8
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title description 7
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 160
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 48
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- -1 3-hydroxypiperidin-1-yl Chemical group 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 15
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 14
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102000001253 Protein Kinase Human genes 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 108060006633 protein kinase Proteins 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 10
- 108091007914 CDKs Proteins 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 239000003080 antimitotic agent Substances 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 230000009223 neuronal apoptosis Effects 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 4
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 abstract description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 165
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 152
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 103
- 239000000243 solution Substances 0.000 description 97
- 239000003921 oil Substances 0.000 description 76
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 69
- 239000011541 reaction mixture Substances 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 239000012267 brine Substances 0.000 description 46
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- 239000002904 solvent Substances 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- 239000007787 solid Substances 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- 238000004809 thin layer chromatography Methods 0.000 description 27
- 239000012300 argon atmosphere Substances 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 239000008346 aqueous phase Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- RZNZEEVYJDIYEJ-UHFFFAOYSA-N n-benzyl-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC=C1 RZNZEEVYJDIYEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000004452 microanalysis Methods 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 7
- 150000003212 purines Chemical class 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 6
- 102000016736 Cyclin Human genes 0.000 description 6
- 108050006400 Cyclin Proteins 0.000 description 6
- 102000003909 Cyclin E Human genes 0.000 description 6
- 108090000257 Cyclin E Proteins 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N dimethyl monosulfide Natural products CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- JAINUFIMBAQRAD-JOCHJYFZSA-N (2r)-2-(tritylamino)butanal Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C=O)C1=CC=CC=C1 JAINUFIMBAQRAD-JOCHJYFZSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000011278 mitosis Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- JAINUFIMBAQRAD-QFIPXVFZSA-N (2s)-2-(tritylamino)butanal Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C=O)C1=CC=CC=C1 JAINUFIMBAQRAD-QFIPXVFZSA-N 0.000 description 4
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2,5-dimethylpyridine Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 102000002427 Cyclin B Human genes 0.000 description 4
- 108010068150 Cyclin B Proteins 0.000 description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- KZXJWVRCUAGBBS-XXBNENTESA-N (2r,3s)-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)[C@@H](C)O)C1=CC=CC=C1 KZXJWVRCUAGBBS-XXBNENTESA-N 0.000 description 3
- KZXJWVRCUAGBBS-WMZHIEFXSA-N (2s,3r)-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)[C@H](C)O)C1=CC=CC=C1 KZXJWVRCUAGBBS-WMZHIEFXSA-N 0.000 description 3
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 3
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 3
- YYRCBGUDILAADB-UHFFFAOYSA-N 2-chloro-n-(3-nitrophenyl)-9-propan-2-ylpurin-6-amine Chemical compound N1=C(Cl)N=C2N(C(C)C)C=NC2=C1NC1=CC=CC([N+]([O-])=O)=C1 YYRCBGUDILAADB-UHFFFAOYSA-N 0.000 description 3
- UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 229910020700 Na3VO4 Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- SZAVVKVUMPLRRS-UHFFFAOYSA-N lithium;propane Chemical compound [Li+].C[CH-]C SZAVVKVUMPLRRS-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 3
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CSJUGIJIZSGDQL-JOCHJYFZSA-N (2r)-2-(tritylamino)butan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CO)CC)C1=CC=CC=C1 CSJUGIJIZSGDQL-JOCHJYFZSA-N 0.000 description 2
- JCBPETKZIGVZRE-SCSAIBSYSA-N (2r)-2-aminobutan-1-ol Chemical compound CC[C@@H](N)CO JCBPETKZIGVZRE-SCSAIBSYSA-N 0.000 description 2
- BKFGLDUWYUYHRF-UHNVWZDZSA-N (2r,3s)-3-aminopentan-2-ol Chemical compound CC[C@H](N)[C@@H](C)O BKFGLDUWYUYHRF-UHNVWZDZSA-N 0.000 description 2
- CSJUGIJIZSGDQL-QFIPXVFZSA-N (2s)-2-(tritylamino)butan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CO)CC)C1=CC=CC=C1 CSJUGIJIZSGDQL-QFIPXVFZSA-N 0.000 description 2
- JCBPETKZIGVZRE-BYPYZUCNSA-N (2s)-2-aminobutan-1-ol Chemical compound CC[C@H](N)CO JCBPETKZIGVZRE-BYPYZUCNSA-N 0.000 description 2
- MKIFEIOSXFUKCO-HSZRJFAPSA-N (3r)-2-methyl-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C(C)(C)O)C1=CC=CC=C1 MKIFEIOSXFUKCO-HSZRJFAPSA-N 0.000 description 2
- RJQQAAMUEHNMSQ-RXMQYKEDSA-N (3r)-3-amino-2-methylpentan-2-ol Chemical compound CC[C@@H](N)C(C)(C)O RJQQAAMUEHNMSQ-RXMQYKEDSA-N 0.000 description 2
- RJQQAAMUEHNMSQ-YFKPBYRVSA-N (3s)-3-amino-2-methylpentan-2-ol Chemical compound CC[C@H](N)C(C)(C)O RJQQAAMUEHNMSQ-YFKPBYRVSA-N 0.000 description 2
- BDXKRPMQAYFDMA-IKOFQBKESA-N (4r)-2,2-dimethyl-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C(O)C(C)(C)C)C1=CC=CC=C1 BDXKRPMQAYFDMA-IKOFQBKESA-N 0.000 description 2
- SBEWMOXIQSCFED-MIHMCVIASA-N (4r)-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C(O)CC)C1=CC=CC=C1 SBEWMOXIQSCFED-MIHMCVIASA-N 0.000 description 2
- XGYNRIMZGAMYNO-PKPIPKONSA-N (4s)-4-amino-2,2-dimethylhexan-3-ol Chemical compound CC[C@H](N)C(O)C(C)(C)C XGYNRIMZGAMYNO-PKPIPKONSA-N 0.000 description 2
- KHRLRJPSKWLLPI-PKPIPKONSA-N (4s)-4-amino-2-methylhexan-3-ol Chemical compound CC[C@H](N)C(O)C(C)C KHRLRJPSKWLLPI-PKPIPKONSA-N 0.000 description 2
- IOYVGJNAPMXLLT-ZBHICJROSA-N (4s)-4-aminohexan-3-ol Chemical compound CC[C@H](N)C(O)CC IOYVGJNAPMXLLT-ZBHICJROSA-N 0.000 description 2
- QAVCQCQQTYJKSO-UHFFFAOYSA-N 2-chloro-11-cyclopropyl-4-methyl-5h-dipyrido[2,3-b:2',3'-f][1,4]diazepin-6-one Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC(Cl)=NC=2N1C1CC1 QAVCQCQQTYJKSO-UHFFFAOYSA-N 0.000 description 2
- HVAIDXRZTGBVJW-UHFFFAOYSA-N 2-fluoro-9-propan-2-yl-n-pyridin-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NC1=CC=CC=N1 HVAIDXRZTGBVJW-UHFFFAOYSA-N 0.000 description 2
- OEYJXZGMHLMOBL-UHFFFAOYSA-N 2-fluoro-9-propan-2-yl-n-pyridin-4-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NC1=CC=NC=C1 OEYJXZGMHLMOBL-UHFFFAOYSA-N 0.000 description 2
- URZANDAAMCTZFA-UHFFFAOYSA-N 2-fluoro-n-(pyridin-4-ylmethyl)-7h-purin-6-amine Chemical compound C=12N=CNC2=NC(F)=NC=1NCC1=CC=NC=C1 URZANDAAMCTZFA-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000002554 Cyclin A Human genes 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 102000002495 Cyclin H Human genes 0.000 description 2
- 108010068237 Cyclin H Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QFFVPLLCYGOFPU-UHFFFAOYSA-N barium chromate Chemical compound [Ba+2].[O-][Cr]([O-])(=O)=O QFFVPLLCYGOFPU-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- VLECDMDGMKPUSK-UHFFFAOYSA-N hydron;piperidin-3-ol;chloride Chemical compound Cl.OC1CCCNC1 VLECDMDGMKPUSK-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- NWYYWIJOWOLJNR-YFKPBYRVSA-N (2r)-2-amino-3-methylbutan-1-ol Chemical compound CC(C)[C@@H](N)CO NWYYWIJOWOLJNR-YFKPBYRVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CVIBDXQYFNZNMA-ZBFHGGJFSA-N (2r,3s)-3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)[C@@H](C)O)=NC=1NCC1=CC=CC=C1 CVIBDXQYFNZNMA-ZBFHGGJFSA-N 0.000 description 1
- CVIBDXQYFNZNMA-GOEBONIOSA-N (2s,3r)-3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CC)[C@H](C)O)=NC=1NCC1=CC=CC=C1 CVIBDXQYFNZNMA-GOEBONIOSA-N 0.000 description 1
- BKFGLDUWYUYHRF-CRCLSJGQSA-N (2s,3r)-3-aminopentan-2-ol Chemical compound CC[C@@H](N)[C@H](C)O BKFGLDUWYUYHRF-CRCLSJGQSA-N 0.000 description 1
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- KZXJWVRCUAGBBS-LEQGEALCSA-N (3r)-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C(C)O)C1=CC=CC=C1 KZXJWVRCUAGBBS-LEQGEALCSA-N 0.000 description 1
- JBFPVHXMCIWHJX-MRXNPFEDSA-N (3r)-3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]-2-methylpentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CC)C(C)(C)O)=NC=1NCC1=CC=CC=C1 JBFPVHXMCIWHJX-MRXNPFEDSA-N 0.000 description 1
- CVIBDXQYFNZNMA-BZSJEYESSA-N (3r)-3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CC)C(C)O)=NC=1NCC1=CC=CC=C1 CVIBDXQYFNZNMA-BZSJEYESSA-N 0.000 description 1
- BKFGLDUWYUYHRF-BRJRFNKRSA-N (3r)-3-aminopentan-2-ol Chemical compound CC[C@@H](N)C(C)O BKFGLDUWYUYHRF-BRJRFNKRSA-N 0.000 description 1
- MKIFEIOSXFUKCO-QHCPKHFHSA-N (3s)-2-methyl-3-(tritylamino)pentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C(C)(C)O)C1=CC=CC=C1 MKIFEIOSXFUKCO-QHCPKHFHSA-N 0.000 description 1
- JBFPVHXMCIWHJX-INIZCTEOSA-N (3s)-3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]-2-methylpentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)C(C)(C)O)=NC=1NCC1=CC=CC=C1 JBFPVHXMCIWHJX-INIZCTEOSA-N 0.000 description 1
- RZROWHATYIVXID-IKOFQBKESA-N (4r)-2-methyl-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CC)C(O)C(C)C)C1=CC=CC=C1 RZROWHATYIVXID-IKOFQBKESA-N 0.000 description 1
- JNYINEBNIROMEU-DUSLRRAJSA-N (4r)-4-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]-2,2-dimethylhexan-3-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@H](CC)C(O)C(C)(C)C)=NC=1NCC1=CC=CC=C1 JNYINEBNIROMEU-DUSLRRAJSA-N 0.000 description 1
- XGYNRIMZGAMYNO-ULUSZKPHSA-N (4r)-4-amino-2,2-dimethylhexan-3-ol Chemical compound CC[C@@H](N)C(O)C(C)(C)C XGYNRIMZGAMYNO-ULUSZKPHSA-N 0.000 description 1
- KHRLRJPSKWLLPI-ULUSZKPHSA-N (4r)-4-amino-2-methylhexan-3-ol Chemical compound CC[C@@H](N)C(O)C(C)C KHRLRJPSKWLLPI-ULUSZKPHSA-N 0.000 description 1
- IOYVGJNAPMXLLT-LWOQYNTDSA-N (4r)-4-aminohexan-3-ol Chemical compound CC[C@@H](N)C(O)CC IOYVGJNAPMXLLT-LWOQYNTDSA-N 0.000 description 1
- BDXKRPMQAYFDMA-SKCDSABHSA-N (4s)-2,2-dimethyl-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C(O)C(C)(C)C)C1=CC=CC=C1 BDXKRPMQAYFDMA-SKCDSABHSA-N 0.000 description 1
- RZROWHATYIVXID-SKCDSABHSA-N (4s)-2-methyl-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C(O)C(C)C)C1=CC=CC=C1 RZROWHATYIVXID-SKCDSABHSA-N 0.000 description 1
- SBEWMOXIQSCFED-UXMRNZNESA-N (4s)-4-(tritylamino)hexan-3-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@@H](CC)C(O)CC)C1=CC=CC=C1 SBEWMOXIQSCFED-UXMRNZNESA-N 0.000 description 1
- JNYINEBNIROMEU-KKFHFHRHSA-N (4s)-4-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]-2,2-dimethylhexan-3-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)C(O)C(C)(C)C)=NC=1NCC1=CC=CC=C1 JNYINEBNIROMEU-KKFHFHRHSA-N 0.000 description 1
- CCMLBTWPLDKEBS-KKFHFHRHSA-N (4s)-4-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]-2-methylhexan-3-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)C(O)C(C)C)=NC=1NCC1=CC=CC=C1 CCMLBTWPLDKEBS-KKFHFHRHSA-N 0.000 description 1
- DCBVAYFYFOLMIC-BHWOMJMDSA-N (4s)-4-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]hexan-3-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)C(O)CC)=NC=1NCC1=CC=CC=C1 DCBVAYFYFOLMIC-BHWOMJMDSA-N 0.000 description 1
- 0 *c1c2nc[n](*)c2nc(*)n1 Chemical compound *c1c2nc[n](*)c2nc(*)n1 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LEWZOBYWGWKNCK-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=C2CCCC2=C1 LEWZOBYWGWKNCK-UHFFFAOYSA-N 0.000 description 1
- MKLISSWTXHIHER-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)-6-morpholin-4-yl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(N)=NC(N2CCN(CC=3C=CC=CC=3)CC2)=NC=1N1CCOCC1 MKLISSWTXHIHER-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MINNUHFZAFXLIX-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-N-[(3,4-dimethoxyphenyl)methyl]purin-6-amine 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-7H-purin-6-amine Chemical compound ClC1=NC(=C2N=CNC2=N1)NCC1=CC(=C(C=C1)OC)OC.ClC1=NC(=C2N=CN(C2=N1)C1CCCC1)NCC1=CC(=C(C=C1)OC)OC MINNUHFZAFXLIX-UHFFFAOYSA-N 0.000 description 1
- BYRONOJBQIIPCK-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-(2,3-dihydro-1h-inden-5-yl)purin-6-amine Chemical compound C12=NC(Cl)=NC(NC=3C=C4CCCC4=CC=3)=C2N=CN1C1CCCC1 BYRONOJBQIIPCK-UHFFFAOYSA-N 0.000 description 1
- OJALXXQLYZBVOR-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-[(3,4-dimethoxyphenyl)methyl]purin-6-amine Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC(Cl)=NC2=C1N=CN2C1CCCC1 OJALXXQLYZBVOR-UHFFFAOYSA-N 0.000 description 1
- CHOHUTWWDHJALH-UHFFFAOYSA-N 2-chloro-n-(3-nitrophenyl)-7h-purin-6-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2C=3N=CNC=3N=C(Cl)N=2)=C1 CHOHUTWWDHJALH-UHFFFAOYSA-N 0.000 description 1
- JUWQLFISPRTAIM-UHFFFAOYSA-N 2-fluoro-n-(pyridin-2-ylmethyl)-7h-purin-6-amine Chemical compound C=12N=CNC2=NC(F)=NC=1NCC1=CC=CC=N1 JUWQLFISPRTAIM-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N 2-pentanol Substances CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- IJDHQFKNYJJHBS-UHFFFAOYSA-N 3-methyl-2-[[6-(3-nitroanilino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol Chemical compound C=12N=CN(C(C)C)C2=NC(NC(CO)C(C)C)=NC=1NC1=CC=CC([N+]([O-])=O)=C1 IJDHQFKNYJJHBS-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000002428 Cyclin C Human genes 0.000 description 1
- 108010068155 Cyclin C Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 101001052492 Mus musculus Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical class 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003226 decolorizating effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010082683 kemptide Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000016853 telophase Effects 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to new 2,6,9-substituted purine derivatives and their biological applications.
- the invention relates to purine derivatives having antiproliferative properties which are useful in the treatment of proliferative disorders such as cancer, leukemia, psoriasis and the like.
- CDK cyclin-dependent kinase
- CDK1 - also known as cdc2, and CDK2 cyclin A
- CDKS cyclin B1-B3
- CDK1 cyclin C
- CDKS cyclin D1-D3
- CDK2 cyclin C
- CDK4 cyclin D1-D3
- CDK9 cyclin H
- CDK7 cyclin H
- CDKs The activity of CDKs is regulated post-translationally, by transitory associations with other proteins, and by alterations of their intracellular localisation. Tumour development is closely associated with genetic alteration and deregulation of CDKs and their regulators, suggesting that inhibitors of CDKs may be useful anti-cancer therapeutics. Indeed, early results suggest that transformed and normal cells differ in their requirement for e.g. cyclin A/CDK2 and that it may be possible to develop novel antineoplastic agents devoid of the general host toxicity observed with conventional cytotoxic and cytostatic drugs.
- CDKs The function of CDKs is to phosphorylate and thus activate or deactivate certain proteins, including e.g. retinoblastoma proteins, lamins, histone HI, and components of the mitotic spindle.
- the catalytic step mediated by CDKs involves a phospho-transfer reaction from ATP to the macromolecular enzyme substrate.
- Several groups of compounds (reviewed in e.g. N. Gray, L. Detivaud, C. Doerig, L. Meijer, Curr. Med. Chem. 1999, 6, 859) have been found to possess anti-proliferative properties by virtue of CDK-specific ATP antagonism.
- WO 98/05335 discloses 2,6,9-trisubstituted purine derivatives that are selective inhibitors of cell cycle kinases. Such compounds are useful in the treatment of autoimmune disorders, e.g. rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis; treating cancer, cardiovascular disease, such as restenosis, host v graft disease, gout, polycystic kidney disease and other proliferative diseases whose pathogenesis involves abnormal cell proliferation.
- autoimmune disorders e.g. rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis
- cardiovascular disease such as restenosis, host v graft disease, gout, polycystic kidney disease and other proliferative diseases whose pathogenesis involves abnormal cell proliferation.
- WO 99/07705 discloses purine analogues that inhibit inter alia protein kinases, G-proteins and polymerases. More specifically, the invention relates to methods of using such purine analogues to treat cellular proliferative disorders and neurodegenerative diseases.
- WO 97/20842 also discloses purine derivatives displaying antiproliferative properties which are useful in treating cancer, psoriasis, and neurodegenerative disorders.
- the present invention seeks to provide new 2,6,9-substituted purine derivatives, particularly those having antiproliferative properties.
- the present invention relates to a compound of formula I
- R is 3-hydroxypiperidin-l-yl, or NHCH(R 4 )CH(R 3 )OH, wherein R 3 is hydrogen or methyl and R 4 is methyl, ethyl or isopropyl; R 6 is 3-nitrophenylamino, 3,4-dimethoxybenzylamino, pyrid-2-yl-methylamino, pyrid- 4-yl-methylamino or indan-5-amino; and
- R 9 is isopropyl or cyclopentanyl.
- R 2 is NHCH(CHMe 2 )CH 2 OH or NHCH(CH 2 Me)CH 2 OH.
- the compound of formula I is selected from the following:
- the invention relates to a compound selected from the following:
- the invention relates to an optical isomer of a compound as described hereinbefore.
- optical isomer is synonymous with the term “enantiomer” and refers to a molecule having a chiral centre which can exist in two different isomeric (so-called “enantiomeric”) forms, each enantiomer being a mirror image of the other.
- R 2 when R 2 is NHCH(R 4 )CH(R 3 ), R 2 may exist in one or more of the following conformations, or mixtures thereof:
- R 2 is 3-hydroxypiperidin-l-yl
- R may exist in one or more of the following conformations, or mixtures thereof:
- the compound of the invention is in the form of a racemate.
- racemate refers to a mixture of equal quantities of the (+) and (-) enantiomers of an optically active compound. Such a mixture exhibits no optical activity, i.e. it does not rotate the plane of polarized light.
- compounds of the invention containing more than one chiral centre may exist as two different stereoisomers, each of which may exist in two enantiomeric forms.
- a second aspect provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the present invention with a pharmaceutically acceptable diluent, excipient or carrier, or a mixture thereof.
- a third aspect relates to the use of a compound of the present invention for treating a proliferative disorder.
- the proliferative disorder is cancer or leukaemia.
- the proliferative disorder is psoriasis.
- the compound is administered in an amount sufficient to inhibit at least one CDK enzyme.
- the CDK enzyme is CDK2.
- the invention relates to the use of a compound of the invention as an anti-mitotic agent.
- Mitosis is the process by which the body grows and replaces cells. Mitosis refers to the indirect division of a cell, consisting of a complex of various processes, by means of which the two daughter nuclei normally receive identical complements of the number of chromosomes characteristic of the somatic cells of the species. Mitosis is divided into four phases: prophase, metaphase, anaphase and telophase.
- mitosis is generally used interchangeably with cell division, but strictly speaking it refers to nuclear division, whereas cytokinesis refers to division of the cytoplasm.
- anti-mitotic agent refers to an agent which inhibits or prevents mitosis and/or cytokinesis.
- the invention relates to the use of a compound of the present invention for treating a neurodegenerative disorder.
- neurodegenerative disorders include central nervous system disorders characterised by a gradual and progressive loss of neural tissue. Examples include Alzheimer's disease and Parkinson's disease. Even more preferably, the compound of the invention is used for treating neuronal apoptosis.
- a sixth aspect relates to the use of a compound of the invention as an antiviral agent.
- the compound of the invention is preferably administered in an amount sufficient to inhibit one or more of the host cell CDKs involved in viral replication, i.e. CDK2, CDK7, CDK8, and CDK9 [Wang D, De la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, Healey M, Stein D, Denny T, Harrison LE, Meijer L, Kashanchi F. Inliibition of human immunodeficiency virus type 1 transcription by chemical cyclin- dependent kinase inhibitors. J. Virol. 2001; 75: 7266-7279].
- CDK2 Hos involved in viral replication
- the compound of the invention may be used to treat one or more viral-related diseases, such as human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV).
- HCMV human cytomegalovirus
- HSV-1 herpes simplex virus type 1
- HSV-1 human immunodeficiency virus type 1
- VZV varicella zoster virus
- a seventh aspect relates to the use of a compound of the present invention in the preparation of a medicament for treating a proliferative disorder.
- the proliferative disorder is cancer or leukaemia.
- preparation of a medicament includes the use of a compound of the invention directly as the medicament in addition to its use in a screening programme for the identification of further agents or in any stage of the manufacture of such a medicament.
- An eighth aspect relates to the use of a compound of the present invention for inhibiting a protein kinase.
- the protein kinase is a cyclin dependent kinase, even more preferably CDK2.
- a ninth aspect provides a method of treating a proliferative disease, said method comprising administering to a mammal a therapeuticaUy effective amount of a compound of the invention.
- treatment includes one or more of curative, palliative and prophylactic treatment.
- treatment includes at least curative treatment and/or palliative treatment.
- said proliferative disorder is cancer or leukaemia.
- the compound of the invention is administered orally.
- a tenth aspect of the invention relates to a method of inhibiting a protein kinase, said method comprising contacting said protein kinase with a compound of the invention.
- said protein kinase is a cyclin dependent kinase, even more preferably CDK2.
- Some of the compounds may exist as stereoisomers and/or geometric isomers, e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and or geometric forms.
- the present invention contemplates the use of all the individual stereoisomers and geometric isomers of those compounds, and mixtures thereof.
- the terms used in the claims encompass these forms, provided said forms retain the appropriate functional activity (though not necessarily to the same degree).
- the present invention also includes the use of solvate forms of the compound of the present invention, including hydrates.
- the terms used in the claims encompass these forms.
- the invention furthermore relates to the compounds of or of use in the present invention (first and seconds aspects) in their various crystalline forms, polymorphic forms and (an)hydrous forms. It is well established within the pharmaceutical industry that chemical compounds may be isolated in any of such forms by slightly varying the method of purification and or isolation form the solvents used in the synthetic preparation of such compounds.
- the present invention also includes the use of pro-drug forms of the compounds of the present invention.
- prodrugs include entities that have certain protected group(s) and which may not possess pharmacological activity as such, but may, in certain instances, be administered (such as orally or parenterally) and thereafter metabolised in the body to form the compounds of the present invention which are pharmacologically active.
- pro-moieties for example as described in "Design of Prodrugs” by H. Bundgaard, Elsevier, 1985 (the disclosured of which is hereby incorporated by reference), may be placed on appropriate functionalities of the compounds. Such prodrugs are also included within the scope of the invention.
- the compound may be a compound mimetic.
- mimetic relates to any chemical which includes, but is not limited to, a peptide, polypeptide, antibody or other organic chemical which has the same qualitative activity or effect as a reference agent.
- the compounds of the present invention may be administered as pharmaceutically acceptable salts.
- a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base, as appropriate.
- the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- Suitable acid addition salts are formed from acids which form non-toxic salts and include the hydrochloride, hydrobromide, hydroiodide, nitrate, sulphate, bisulphate, phosphate, hydrogenphosphate, acetate, trifluoroacetate, gluconate, lactate, salicylate, citrate, tartrate, ascorbate, succinate, maleate, fumarate, gluconate, formate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate and p-toluenesulphonate salts.
- suitable pharmaceutically acceptable base addition salts can be formed from bases which form non-toxic salts and include the aluminium, calcium, lithium, magnesium, potassium, sodium, zinc, and pharmaceutically-active amines such as diethanolamine salts.
- the compounds of the present invention may contain one or more asymmetric carbon atoms and therefore exists in two or more stereoisomeric forms.
- the present invention includes the individual stereoisomers of the compound and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
- Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of the agent or a suitable salt or derivative thereof.
- An individual enantiomer of the compound may be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
- the present invention also includes all suitable isotopic variations of the compound or a pharmaceutically acceptable salt thereof.
- An isotopic variation of an compound of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- isotopes that can be incorporated into the compound and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen and oxygen, such as 2 H, 3 H, 13 C, 14 C, 1S N, 17 O and 18 O respectively.
- isotopic variations of the compound and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the compound of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- the present invention also includes (wherever appropriate) the use of zwitterionic forms of the compounds of the present invention.
- the component(s) of the present invention may be formulated into a pharmaceutical composition, such as by mixing with one or more of a suitable carrier, diluent or excipient, by using techniques that are known in the art.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeuticaUy effective amount of one or more compounds and a pharmaceutically acceptable carrier, diluent or excipient (including combinations thereof).
- the pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient.
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
- the choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice.
- the pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).
- suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.
- suitable diluents include ethanol, glycerol and water.
- Suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.
- Suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
- preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
- Antioxidants and suspending agents may be also used.
- the pharmaceutical composition of the present invention may be formulated to be administered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route.
- the formulation may be designed to be administered by a number of routes.
- the components of the present invention may be administered alone but will generally be administered as a pharmaceutical composition - e.g. when the components are in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- composition can be administered (e.g. orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
- the tablet may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropyl- methylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
- excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
- disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates
- Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
- Preferred excipients in this regard include lactose, starch, cellulose, milk sugar or high molecular weight polyethylene glycols.
- the compound may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
- the routes for administration include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestable solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracere- . broventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, vaginal, epidural, sublingual.
- oral e.g. as a tablet, capsule, or as an ingestable solution
- mucosal e.g. as a nasal spray or aerosol for inhalation
- nasal parenteral (e.g. by an injectable form)
- gastrointestinal intraspinal, intra
- composition comprises more than one compound
- hot all of the components of the pharmaceutical need be administered by the same route.
- composition comprises more than one active component, then those components may be administered by different routes.
- a component of the present invention is administered parenterally
- examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly or subcutaneously administering the component; and/or by using infusion techniques.
- the component is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
- suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- the component(s) of the present invention can be administered intranasally or by inhalation and is conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2- tetrafluoroethane (HFA 134 ATM) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EATM), carbon dioxide or other suitable gas.
- a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2- tetrafluoroethane (HFA 134 ATM)
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate.
- a lubricant e.g. sorbitan trioleate.
- Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the agent and a suitable powder base such as lactose or starch.
- the component(s) of the present invention can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
- the component(s) of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route.
- the compounds can be formulated as micronised suspensions in isotomc, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride.
- a preservative such as a benzylalkonium chloride.
- they may be formulated in an ointment such as petrolatum.
- the component(s) of the present invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol,
- the pharmaceutical composition is administered orally.
- a physician will determine the actual dosage which will be most suitable for an individual subject.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
- the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
- agents identified by any such assay method may be used as therapeutic agents - i.e. in therapy applications.
- the term “therapy” includes curative effects, alleviation effects, and prophylactic effects.
- the therapy may be on humans or animals.
- composition is to be administered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.
- the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously.
- the compositions may be best used in the form of a sterile aqueous solution- which may. contain other substances, for example , enough salts or monosaccharides to make the solution isotonic with blood.
- buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
- one or more compounds may also be used in combination with a cyclodextrin.
- Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes.
- the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser.
- Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A- 98/55148.
- Another aspect of the invention relates to the use of a compound as defined hereinabove in an assay for identifying further candidate compounds that influence the activity of one or more CDK enzymes.
- the assay is capable of identifying candidate compounds that are capable of inhibiting one or more CDK enzymes. More preferably, the assay is a competitive binding assay.
- the candidate compound is generated by conventional SAR modification of a compound of the invention.
- conventional SAR modification refers to standard methods known in the art for varying a given compound by way of chemical derivatisation.
- the identified compound may act as a model (for example, a template) for the development of other compounds.
- the compounds employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between the compound and the agent being tested may be measured.
- the assay of the present invention may be a screen, whereby a number of agents are tested.
- the assay method of the present invention is a high through-put screen.
- Techniques for drug screening may be based on the method described in Geysen, European Patent Application 84/03564, published on September 13, 1984.
- large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface.
- the peptide test compounds are reacted with a suitable compound or fragment thereof and washed. Bound entities are then detected - such as by appropriately adapting methods well known in the art.
- a purified compound can also be coated directly onto plates for use in a drug screening techniques.
- non-neutralising antibodies can be used to capture the peptide and immobilise it on a solid support.
- This invention also contemplates the use of competitive drug screening assays in which neutralising antibodies capable of binding a compound specifically compete with a test compound for binding to a compound.
- Another technique for screening provides for high throughput screening (HTS) of agents having suitable binding affinity to the substances and is based upon the method described in detail in WO 84/03564.
- the 3 '-methyl substituted diasteriomers (7 and 8) initially underwent Swern oxidation to their respective ketones (23 and 24), followed by introduction of the second 3 '-methyl using methylmagnesium iodide in refmxing ether.
- 6-benzylamino-, 6-(pyridin-2-ylmethyl), 6-(pyridin-3-ylmethyl) and 6-(pyridin-2-ylmethyl)- intermediates the initial step involved reaction of 6-chloro- 2-fluoro-purine 29 [Gray, N.S.; Kwon, S.; Schultz, P.G. Tetrahedron Lett, 1997, 38 (7), 1161-1164] with either benzylamine, 2-(aminomethyl)pyridine, 3- (aminomethyl)pyridine or 4-(aminomethyl)pyridine, in n-BuOH the presence of DIPEA, to afford the corresponding 6-substituted intermediates 30.
- reaction mixture was stirred at 0°C for 3 h, and then allowed to return to RT over 30 min. and stirred at this temperature for 1 h, when TLC (9:1 CHCl3/ eOH) indicated that the reaction had gone to completion.
- the solvent was evaporated in vacuo and the residue partitioned between citric acid solution (200 mL, 10 % aq) and EtOAc (200 mL), the aqueous phase was separated and extracted with more EtOAc (2 x 100 mL).
- the pH of the aqueous phase was adjusted to 7.0 with NaOH solution (50 % w/v, aq), extracted with
- reaction mixture was stirred at this temperature for 2 h and then at -55 °C for 4 h, when TLC (8:2 hexane/Et 2 O) indicated that the reaction had gone to completion.
- TLC 8:2 hexane/Et 2 O
- To the reaction mixture was added a saturated aqueous solution of NH CI (100 mL) and allowed to warm to RT over 16 h.
- the reaction mixture was extracted with Et 2 O (2 x 200 mL), and the combined organic phase washed with brine (50 mL), dried (MgSO ) and evaporated in vacuo.
- reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 48 h, when TLC (55:40:5 CH 2 Cl 2 /Et 2 O/MeOH) indicated the appearance of a lower running product together with some desired product.
- the reaction mixture was allowed to cool to RT and the solvent was evaporated in vacuo.
- the residue was partitioned between CH 2 C1 2 (100 mL) and H O (200 mL), the aqueous phase was extracted with more CH 2 C1 2 (3 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- the residue was purified by gradient column chromatography on silica gel eluted with CH 2 Cl 2 /Et 2 O/MeOH (60:40:0 ⁇ 60:40:4) to afford the title compound as a white solid
- reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h, when TLC DCM:ether:MeOH (55:40:5) indicated that the reaction had gone to completion.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1:1, 100 mL), the aqueous phase-was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h, when TLC DCM:ether:MeOH (55:40:5) indicated that the reaction had gone to completion.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1 :1, 100 mL), the aqueous phase was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- Example 11 3RS.4i?)-4-r6-Benzylamino.-9-isopropyl-9H-purin-2-ylamino -2-methyl-hexan-3-ol . .
- reaction mixture was stirred at this temperature for 1 h, then allowed to warm to -55 °C and stirred at this temperature for 3h.
- a saturated aqueous solution of NH 4 C1 100 mL was added.
- the reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1:1, 100 mL), the aqueous phase was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- the reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1:1, 100 mL), the aqueous phase was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- (3RS, 4S)-4-Amino-2, 2-dimethyl-hexan-3-ol To a stirred solution of (3RS,4S)-2,2-dimethyl-4-(trityl-amino)-hexan-3-ol (0.47 g, 1 eq, 1.21 mmol) in DCM (10 mL) under an argon atmosphere at room temperature, was added trifluoroacetic acid (5 mL) dropwise, and the solution was stirred at this temperature for 1 h. The solvent was evaporated in vacuo, the residue was precipitated from ether (3 mL) with hexane (20 mL) with stirring to give a yellow oil.
- the reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1:1, 100 mL), the aqueous phase was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO ) and evaporated in vacuo.
- reaction mixture was stirred at this temperature for 4 h, when TLC (hexane:ether; 80:20) indicated that the reaction had gone to completion.
- N-ethylpiperidine 7.54 mL, 5 eq, 54.88 mmol
- the reaction mixture was diluted with more DCM (50 mL) and washed with water
- the reaction mixture was placed in a preheated oil bath at 140 °C and stirred at this temperature for 72 h.
- the reaction mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo.
- the residue was partitioned between EtOAc (50 mL) and brine/water (1:1, 100 mL), the aqueous phase was extracted with more EtOAc (2 x 50 mL), and the combined organic phase was washed with brine (50 mL), dried (MgSO ) and evaporated in vacuo.
- reaction mixture was stirred at this temperature for 4 h, when TLC (hexane: ether; 80:20) indicated that the reaction had gone to completion.
- N-ethylpiperidine (6.71 mL, 5 eq, 48.84 mmol)
- the reaction mixture was diluted with more DCM (50 mL) and washed with water (200 mL).
- the aqueous phase was extracted with DCM (2 x 50 mL), and the combined organic phase washed with brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo.
- the biological activity of the compounds of the invention was demonstrated by measuring the CDK inhibition by virtue of an assay-based screen, and/or by a cytotoxicity assay using one or more cell lines. The results are shown below in Tables 1 and 2.
- CDK2/cyclin E Selected compounds from the above examples were investigated for their CDK2/cyclin E, CDKl/cyclin B, CDK4/cyclin D 1 and CDK7/cyclin H activity.
- Assays for CDK2/cyclin E kinase, CDKl/cyclin B and CDK4/cyclin Dl may be carried out by monitoring phosphorylation of GST-Rb in an appropriate system.
- Rb phosphorylation, induced by CDK2/Cyclin E, CDKl/cyclin B or CDK4/cyclin Dl is determined by incorporation of radiolabelled phosphate in GST-Rb(772-928) using radiolabelled ATP in 96-well format in vitro kinase assay.
- the phosphorylation reaction mixture (total volume 40 ⁇ l) consisted of 50 mM HEPES pH 7.4, 20 mM
- CDK2 may be obtained from available sources or produced by recombinant methods as described. His-tagged CDK2/Cyclin E and CDKl/Cyclin B may be co-expressed in Sf 9 insect cells infected with the appropriate baculovirus constructs. The cells are harvested two days after infection by low speed centrifugation and the proteins purified from the insect cell pellets by Metal-chelate chromatography. Briefly, the insect cell pellet is lysed in Buffer A (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.02% NP40 and 5 mM ⁇ -marcaptoethanol, 1 mM NaF.
- Buffer A (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.02% NP40 and 5 mM ⁇ -marcaptoethanol, 1 mM NaF.
- the purified proteins are extensively dialyzed against Storage buffer (20 mM HEPES pH 7.4, 50 mM NaCl, 2 mM DTT, 1 mM EDTA, 1 mM EGTA, 0.02% NP40, 10% v/v Glycerol) aliquoted and stored at -70°C.
- PKC- ⁇ - 6 x His may be purified the same way but using different buffers- 50 mM NaH2PO4, pH 8.0 and
- Triton X-100 instead of Tris andNP40 respectively.
- ERK-2 kinase activity was measured by the incorporation of radioactive phosphate into myelin basic protein (MBP), catalysed by purified mouse ERK-2 (Upstate Biotechnologies).
- the reaction mixture (total volume 50 ⁇ L) consisted of 20 mM MOPS, pH 7.0, 25 mM ⁇ -glycerophosphate, 5 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 4 , 10 mM MgCl 2 , 100 ⁇ M ATP, 0.2 ⁇ Ci [ ⁇ - 32 P]-ATP.
- PKA kinase activity was measured by incorporation of radioactive phosphate into the peptide Kemptide (Fluka Biochemika Cat. 60645), catalysed by cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487).
- the reaction mixture (total volume 50 ⁇ L) consisted of 20 mM MOPS, pH 7.2, 25 mM ⁇ -glycerophosphate, 5 mM
- EGTA 1 mM DTT, 1 mMNa 3 VO , 10 mM MgCl 2 , 100 ⁇ M ATP, 0.2 ⁇ Ci [ 32 P]-ATP.
- Patent Appl. WO 97/20842 comprises oxidation of the carbinol group to a carboxyl group and subsequent excretion of this metabolite [Nutley, B.P., Raynaud, F.I., Wilson, S.C., Fischer, P., McClue, S., Goddard, P.M., Jarman, M., Lane, D., and
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT02738404T ATE301123T1 (en) | 2001-06-27 | 2002-06-27 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES |
DE60205376T DE60205376T2 (en) | 2001-06-27 | 2002-06-27 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES |
EP02738404A EP1399446B1 (en) | 2001-06-27 | 2002-06-27 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
JP2003508946A JP4381804B2 (en) | 2001-06-27 | 2002-06-27 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative diseases |
US10/742,237 US7612079B2 (en) | 2001-06-27 | 2003-12-18 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0115713A GB0115713D0 (en) | 2001-06-27 | 2001-06-27 | New purine derivatives |
GB0115713.0 | 2001-06-27 | ||
GB0120333A GB0120333D0 (en) | 2001-08-21 | 2001-08-21 | New purine derivatives |
GB0120333.0 | 2001-08-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/742,237 Continuation US7612079B2 (en) | 2001-06-27 | 2003-12-18 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002565A1 true WO2003002565A1 (en) | 2003-01-09 |
Family
ID=26246255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/002962 WO2003002565A1 (en) | 2001-06-27 | 2002-06-27 | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
Country Status (7)
Country | Link |
---|---|
US (1) | US7612079B2 (en) |
EP (1) | EP1399446B1 (en) |
JP (1) | JP4381804B2 (en) |
AT (1) | ATE301123T1 (en) |
DE (1) | DE60205376T2 (en) |
GB (1) | GB2378180B8 (en) |
WO (1) | WO2003002565A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016612A2 (en) * | 2002-08-15 | 2004-02-26 | Cyclacel Limited | New purine derivatives |
WO2006021803A2 (en) | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
WO2006024858A1 (en) * | 2004-09-01 | 2006-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | 4-arylazo-3,5-diamino-pyrazole compounds and use thereof |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
WO2008116911A1 (en) * | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
WO2008122767A3 (en) * | 2007-04-04 | 2008-12-31 | Cyclacel Ltd | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
WO2010103473A1 (en) * | 2009-03-10 | 2010-09-16 | Chu De Brest | Method of treatment of polycystic diseases and chronic lymphocytic leukemia |
US7858813B2 (en) | 2004-08-19 | 2010-12-28 | Dsm Ip Assets B.V. | Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products |
EP2330908A1 (en) * | 2008-08-15 | 2011-06-15 | Georgetown University | Fluorescent cdk inhibitors for treatment of cancer |
US8431583B2 (en) | 2007-09-12 | 2013-04-30 | Centre National De La Recherche Scientifique | Use of purine derivatives for the manufacture of a medicament |
US8889861B2 (en) | 2010-01-22 | 2014-11-18 | Cyclacel Limited | Crystalline forms of a purine derivative |
US9884848B2 (en) | 2012-06-26 | 2018-02-06 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
WO2018138500A1 (en) | 2017-01-26 | 2018-08-02 | Cyclacel Limited | Process for preparing purine derivatives |
WO2021148793A1 (en) | 2020-01-22 | 2021-07-29 | Cyclacel Limited | Process for the preparation of purine derivatives exhibiting cdk inhibitory activity |
CN113795493A (en) * | 2019-03-20 | 2021-12-14 | 索邦大学 | Roscovitine analogs and their use for treating rare biliary disorders |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2741881B1 (en) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS |
US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
FR2806626B1 (en) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | USE OF MODULATING SUBSTANCES FOR THE EXPRESSION OR FUNCTION OF A PROTEIN INVOLVED IN THE CELL CYCLE FOR THE TREATMENT OR PREVENTION OF ACUTE NEURAL INJURIES |
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016452A1 (en) * | 1995-11-01 | 1997-05-09 | Novartis Ag | Purine derivatives and processes for their preparation |
WO1997020842A1 (en) * | 1995-12-01 | 1997-06-12 | Centre National De La Recherche Scientifique (C.N.R.S.) | Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof |
WO1998016528A1 (en) * | 1996-10-11 | 1998-04-23 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
WO1999034018A1 (en) * | 1997-12-24 | 1999-07-08 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
WO1999043676A2 (en) * | 1998-02-26 | 1999-09-02 | Aventis Pharmaceuticals Inc. | 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines |
WO2000044750A1 (en) * | 1999-02-01 | 2000-08-03 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) |
WO2000055161A1 (en) * | 1999-03-17 | 2000-09-21 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL131828C (en) * | 1961-05-04 | |||
US3610721A (en) * | 1969-10-29 | 1971-10-05 | Du Pont | Magnetic holograms |
US3853676A (en) * | 1970-07-30 | 1974-12-10 | Du Pont | Reference points on films containing curved configurations of magnetically oriented pigment |
US3676273A (en) * | 1970-07-30 | 1972-07-11 | Du Pont | Films containing superimposed curved configurations of magnetically orientated pigment |
IT938725B (en) * | 1970-11-07 | 1973-02-10 | Magnetfab Bonn Gmbh | PROCEDURE AND DEVICE FOR EIGHT BLACK DRAWINGS IN SURFACE LAYERS BY MEANS OF MAGNETIC FIELDS |
US3790407A (en) * | 1970-12-28 | 1974-02-05 | Ibm | Recording media and method of making |
US4011009A (en) * | 1975-05-27 | 1977-03-08 | Xerox Corporation | Reflection diffraction grating having a controllable blaze angle |
US4398798A (en) * | 1980-12-18 | 1983-08-16 | Sperry Corporation | Image rotating diffraction grating |
JPH0298811A (en) * | 1988-10-05 | 1990-04-11 | Fuji Photo Film Co Ltd | Magnetic recording medium |
WO1990009178A1 (en) | 1989-01-31 | 1990-08-23 | Whitby Research, Inc. | N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists |
US5192611A (en) * | 1989-03-03 | 1993-03-09 | Kansai Paint Co., Ltd. | Patterned film forming laminated sheet |
EP0556449B1 (en) * | 1992-02-21 | 1997-03-26 | Hashimoto Forming Industry Co., Ltd. | Painting with magnetically formed pattern and painted product with magnetically formed pattern |
GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
US5672410A (en) * | 1992-05-11 | 1997-09-30 | Avery Dennison Corporation | Embossed metallic leafing pigments |
US5991078A (en) * | 1992-08-19 | 1999-11-23 | Dai Nippon Printing Co., Ltd. | Display medium employing diffraction grating and method of producing diffraction grating assembly |
JP2655551B2 (en) * | 1992-09-09 | 1997-09-24 | 工業技術院長 | Fine surface shape creation method |
US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
CN1045822C (en) * | 1993-07-16 | 1999-10-20 | 拉科奥夫显示器公司 | Diffractive display utilizing reflective or transmissive light yielding single pixel full color capability |
US6033782A (en) * | 1993-08-13 | 2000-03-07 | General Atomics | Low volume lightweight magnetodielectric materials |
EP0644508B1 (en) * | 1993-08-31 | 1999-12-22 | Control Module, Inc. | Secure optical identification method and means |
JP3396924B2 (en) | 1993-09-07 | 2003-04-14 | 日本曹達株式会社 | Activated sludge bulking inhibitor |
DE4335308C2 (en) * | 1993-10-16 | 1995-12-14 | Daimler Benz Ag | Identification of vehicles to make theft and / or unauthorized sale more difficult |
EP0665229B1 (en) | 1994-02-01 | 1999-11-17 | Ajinomoto Co., Inc. | Process for the production of nucleic acid base derivatives |
US5424119A (en) * | 1994-02-04 | 1995-06-13 | Flex Products, Inc. | Polymeric sheet having oriented multilayer interference thin film flakes therein, product using the same and method |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
GB9524862D0 (en) * | 1995-12-06 | 1996-02-07 | The Technology Partnership Plc | Colour diffractive structure |
US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
US6103361A (en) * | 1997-09-08 | 2000-08-15 | E. I. Du Pont De Nemours And Company | Patterned release finish |
US6168100B1 (en) * | 1997-10-23 | 2001-01-02 | Toyota Jidosha Kabushiki Kaisha | Method for producing embossed metallic flakelets |
US6692031B2 (en) * | 1998-12-31 | 2004-02-17 | Mcgrew Stephen P. | Quantum dot security device and method |
CZ27399A3 (en) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments |
US6808806B2 (en) * | 2001-05-07 | 2004-10-26 | Flex Products, Inc. | Methods for producing imaged coated articles by using magnetic pigments |
US6841238B2 (en) * | 2002-04-05 | 2005-01-11 | Flex Products, Inc. | Chromatic diffractive pigments and foils |
US6749936B2 (en) * | 2001-12-20 | 2004-06-15 | Flex Products, Inc. | Achromatic multilayer diffractive pigments and foils |
US6692830B2 (en) * | 2001-07-31 | 2004-02-17 | Flex Products, Inc. | Diffractive pigment flakes and compositions |
US6949644B2 (en) * | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
AU2002342051B2 (en) * | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
-
2002
- 2002-06-27 WO PCT/GB2002/002962 patent/WO2003002565A1/en active IP Right Grant
- 2002-06-27 DE DE60205376T patent/DE60205376T2/en not_active Expired - Lifetime
- 2002-06-27 AT AT02738404T patent/ATE301123T1/en active
- 2002-06-27 JP JP2003508946A patent/JP4381804B2/en not_active Expired - Fee Related
- 2002-06-27 GB GB0214909A patent/GB2378180B8/en not_active Expired - Fee Related
- 2002-06-27 EP EP02738404A patent/EP1399446B1/en not_active Expired - Lifetime
-
2003
- 2003-12-18 US US10/742,237 patent/US7612079B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016452A1 (en) * | 1995-11-01 | 1997-05-09 | Novartis Ag | Purine derivatives and processes for their preparation |
WO1997020842A1 (en) * | 1995-12-01 | 1997-06-12 | Centre National De La Recherche Scientifique (C.N.R.S.) | Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof |
WO1998016528A1 (en) * | 1996-10-11 | 1998-04-23 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
WO1999034018A1 (en) * | 1997-12-24 | 1999-07-08 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
WO1999043676A2 (en) * | 1998-02-26 | 1999-09-02 | Aventis Pharmaceuticals Inc. | 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines |
WO2000044750A1 (en) * | 1999-02-01 | 2000-08-03 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) |
WO2000055161A1 (en) * | 1999-03-17 | 2000-09-21 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents |
Non-Patent Citations (12)
Title |
---|
CHANG Y-T ET AL: "SYNTHESIS AND APPLICATION OF FUNCTIONALLY DIVERSE 2,6,9,-TRISUBSTITUTED PURINE LIBRARIES AS CDK INHIBITORS", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 6, June 1999 (1999-06-01), pages 361 - 375, XP000926236, ISSN: 1074-5521 * |
DE AZEVEDO W F ET AL: "Inhibition of cyclin-dependent kinases by purine analogues. Crystal Structure of human cdk2 complexed with roscovitine", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 243, no. 1/2, 1997, pages 518 - 526, XP002084931, ISSN: 0014-2956 * |
DUCROT, PIERRE ET AL: "3D-QSAR CoMFA on Cyclin-Dependent Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY ( 2000 ), 43(22), 4098-4108, XP002211201 * |
GIOCANTI N ET AL: "IN VITRO EVALUATION OF A NOVEL 2,6,9-TRISUBSTITUTED PURINE ACTING AS A CYCLIN-DEPENDENT KINASE INHIBITOR", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 886, 1999, pages 180 - 182, XP000974318, ISSN: 0077-8923 * |
GRAY N ET AL: "ATP-SITE DIRECTED INHIBITORS OF CYCLIN-DEPENDENT KINASES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 9, September 1999 (1999-09-01), pages 859 - 875, XP000856195, ISSN: 0929-8673 * |
GRAY, NATHANAEL S. ET AL: "Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors", SCIENCE (WASHINGTON, D. C.) ( 1998 ), 281(5376), 533-538, XP002211200 * |
IMBACH P ET AL: "2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 1, January 1999 (1999-01-01), pages 91 - 96, XP004154784, ISSN: 0960-894X * |
LEGRAVEREND M ET AL: "SYNTHESIS AND IN VITRO EVALUATION OF NOVEL 2,6,9-TRISUBSTITUTED PURINES ACTING AS CYCLIN-DEPENDENT KINASE INHIBITORS", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, no. 7, 1999, pages 1281 - 1293, XP000916148, ISSN: 0968-0896 * |
LEGRAVEREND M ET AL: "Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 7, 7 April 1998 (1998-04-07), pages 793 - 798, XP004136967, ISSN: 0960-894X * |
OH, CHANG-HYUN ET AL: "Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor", ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) ( 1999 ), 332(6), 187-19, XP002211199 * |
SCHOW, STEVEN R. ET AL: "Synthesis and activity of 2,6,9-trisubstituted purines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS ( 1997 ), 7(21), 2697-2702, XP002211198 * |
VESELY J ET AL: "INHIBITION OF CYCLIN-DEPENDENT KINASES BY PURINE ANALOGUES", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 224, no. 2, 1 September 1994 (1994-09-01), pages 771 - 786, XP000576956, ISSN: 0014-2956 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US7582642B2 (en) | 2002-08-15 | 2009-09-01 | Cyclacel Limited | Purine derivatives |
WO2004016612A3 (en) * | 2002-08-15 | 2004-07-01 | Cyclacel Ltd | New purine derivatives |
US8846696B2 (en) | 2002-08-15 | 2014-09-30 | Cyclacel Limited | Purine derivatives |
WO2004016612A2 (en) * | 2002-08-15 | 2004-02-26 | Cyclacel Limited | New purine derivatives |
US7129244B2 (en) | 2003-09-18 | 2006-10-31 | Conforma Therapeutics Corporation | Triazolopyrimidines and related analogs as HSP90-inhibitors |
US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
US7858813B2 (en) | 2004-08-19 | 2010-12-28 | Dsm Ip Assets B.V. | Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products |
WO2006021803A2 (en) | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
WO2006024858A1 (en) * | 2004-09-01 | 2006-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | 4-arylazo-3,5-diamino-pyrazole compounds and use thereof |
US8357673B2 (en) | 2004-09-01 | 2013-01-22 | Univerzita Palackeho V Olomouci | 4-arylazo-3,5-diamino-pyrazole compounds and use thereof |
WO2008116911A1 (en) * | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
US9340544B2 (en) | 2007-03-28 | 2016-05-17 | Ataxion, Inc. | Purinyl derivatives and their use as potassium channel modulators |
US8362024B2 (en) | 2007-03-28 | 2013-01-29 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
AU2008235361B2 (en) * | 2007-04-04 | 2013-02-14 | Cancer Research Technology Limited | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
WO2008122767A3 (en) * | 2007-04-04 | 2008-12-31 | Cyclacel Ltd | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
US8592581B2 (en) | 2007-04-04 | 2013-11-26 | Cyclacel Limited | Trisubstituted purine derivatives |
CN101679434B (en) * | 2007-04-04 | 2013-09-25 | 西克拉塞尔有限公司 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
RU2500400C2 (en) * | 2007-09-12 | 2013-12-10 | Сентр Насьональ Де Ла Решерш Сьентифик | Using purine derivatives for preparing drug preparation |
US8431583B2 (en) | 2007-09-12 | 2013-04-30 | Centre National De La Recherche Scientifique | Use of purine derivatives for the manufacture of a medicament |
EP2330908A4 (en) * | 2008-08-15 | 2011-11-23 | Univ Georgetown | Fluorescent cdk inhibitors for treatment of cancer |
EP2330908A1 (en) * | 2008-08-15 | 2011-06-15 | Georgetown University | Fluorescent cdk inhibitors for treatment of cancer |
US9408848B2 (en) | 2008-08-15 | 2016-08-09 | Georgetown University | Fluorescent CDK inhibitors for treatment of cancer |
WO2010103473A1 (en) * | 2009-03-10 | 2010-09-16 | Chu De Brest | Method of treatment of polycystic diseases and chronic lymphocytic leukemia |
US8889861B2 (en) | 2010-01-22 | 2014-11-18 | Cyclacel Limited | Crystalline forms of a purine derivative |
US9573951B2 (en) | 2010-01-22 | 2017-02-21 | Cyclacel Limited | Crystalline forms of a purine derivative |
US9884848B2 (en) | 2012-06-26 | 2018-02-06 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
WO2018138500A1 (en) | 2017-01-26 | 2018-08-02 | Cyclacel Limited | Process for preparing purine derivatives |
US10927113B2 (en) | 2017-01-26 | 2021-02-23 | Cyclacel Limited | Process for preparing purine derivatives |
EP4212533A1 (en) | 2017-01-26 | 2023-07-19 | Cyclacel Limited | Process for preparing purine derivatives |
CN113795493A (en) * | 2019-03-20 | 2021-12-14 | 索邦大学 | Roscovitine analogs and their use for treating rare biliary disorders |
WO2021148793A1 (en) | 2020-01-22 | 2021-07-29 | Cyclacel Limited | Process for the preparation of purine derivatives exhibiting cdk inhibitory activity |
Also Published As
Publication number | Publication date |
---|---|
EP1399446A1 (en) | 2004-03-24 |
GB2378180B (en) | 2004-01-28 |
JP2004521148A (en) | 2004-07-15 |
EP1399446B1 (en) | 2005-08-03 |
GB0214909D0 (en) | 2002-08-07 |
DE60205376D1 (en) | 2005-09-08 |
US20050009846A1 (en) | 2005-01-13 |
US7612079B2 (en) | 2009-11-03 |
JP4381804B2 (en) | 2009-12-09 |
GB2378180A (en) | 2003-02-05 |
ATE301123T1 (en) | 2005-08-15 |
DE60205376T2 (en) | 2006-04-06 |
GB2378180A8 (en) | 2009-10-21 |
GB2378180B8 (en) | 2009-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1399446B1 (en) | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | |
US8846696B2 (en) | Purine derivatives | |
US7544689B2 (en) | Purine derivatives | |
JP2004516297A (en) | Inhibitors of cyclin dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) | |
US20100197914A1 (en) | Purine Derivatives as Adenosine Al Receptor Ligands | |
JPH06211856A (en) | Anitiparkinosonism agent | |
Kozan et al. | Synthesis and Molecular Docking Studies of New Pyrimidinone ring Containing 1, 2, 3-Triazole Derivatives | |
JP2001523213A (en) | Trisubstituted thioxanthines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002738404 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10742237 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003508946 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738404 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002738404 Country of ref document: EP |